A preparation containing unsaponifiable fractions of avocado oil and soybean oil in the treatment of osteoarthritis Review article
Article Sidebar
Published:
Jun 20, 2022
Keywords:
osteoarthritis, unsaponifiables of avocado and soybean, slow-acting symptomatic drugs used in the treatment of osteoarthritis
Main Article Content
Abstract
The medication containing unsaponifiable fractions of avocado and soybean oil is a mixture obtained according to a strictly defined procedure. It is a drug that has been used for a long time in management patients with osteoarthritis and has anti-inflammatory, analgesic and chondroprotective effects. The drug is classified as the slow-acting symptomatic drugs used in the treatment of osteoarthritis. The effects of piascledine have been evidenced in in vitro studies, animal models and clinical investigations. The drug has been shown to reduce rest and walking pain, reduce use of the non-steroidal anti-inflammatory drugs and other analgesics, and improve the functional status of the musculoskeletal system. Described drug is very well tolerated and shows no interactions with other medications.
Article Details
How to Cite
Kucharz, E. J. (2022). A preparation containing unsaponifiable fractions of avocado oil and soybean oil in the treatment of osteoarthritis. Medycyna Faktow (J EBM), 15(2(55), 224-227. https://doi.org/10.24292/01.MF.0222.16
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020; 104: 293-311.
2. Glyn-Jones S, Palmer AJR, Agricola R et al. Osteoarthritis. Lancet. 2015; 386(9991): 376-87.
3. Romanowski W. Choroba zwyrodnieniowa stawów. In: Olesińska M (ed). Reumatologia. PZWL, Warszawa 2019: 279-90.
4. Kucharz EJ, Kovalenko V, Szántó S et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016; 32: 997-1004.
5. Kucharz EJ. Leczenie farmakologiczne choroby zwyrodnieniowej. Twój Magazyn Med. 2003; 8(14-131): 49-56.
6. Kucharz EJ. Zachowawcze leczenie choroby zwyrodnieniowej stawów. Terapia. 2007; 15(12): 21-6.
7. Kucharz EJ. Hit two birds with one stone: why crystalline glucosamine sulphate used for osteoarthritis medication is beneficial for patients with risk of cardiovascular disorders. Reumatologia. 2019; 57: 306.
8. Kucharz EJ. Zastosowanie mieszaniny niezmydlających się składników olejów z awokado i soi (piaskledyny) w leczeniu choroby zwyrodnieniowej stawów. Ortop Traumatol Rehabil. 2003; 5: 248-51.
9. Henrotin YE, Labasse AH, Jaspar JM et al. Effects of three avocado/soyabean unsaponifiable mixture on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheum. 1998; 17: 31-9.
10. Mauviel A, Daireaux M, Hartman DJ et al. Effets insaponifiables d’avocado/soja sur la production de collagene par des cultures de synoviocytes, chondrocytes articulaires et fibroblastes dermiques. Rev Rhum. 1989; 56: 207-13.
11. Boumediene K, Felisaz N, Bogdanowicz P et al. Avocado/soyabean unsaponifiables enhance the expression of transforming growth factor β1 and β2 in cultured articular chondrocytes. Arthritis Rheum. 1999; 42: 148-56.
12. Blotman F, Maheu E, Wulwik A et al. Efficacy and safety of avocado/soyabean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997; 64: 825-34.
13. Appelboom T, Schuermans J, Verbruggen G et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol. 2001; 30: 242-7.
14. Lequesne M, Maheu E, Cadet C et al. Effect of avocado/soya unsaponifiables on joint space loss in hip osteoarthritis over 2 years. A placebo controlled trial. Arthritis Rheum. 1996; 39: S227.
15. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016; 54: 217-26.
16. Honvo G, Reginster JY, Rabenda V et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a systematic review and meta- -analysis. Drugs Aging. 2019; 36(suppl 1): 65-99.
2. Glyn-Jones S, Palmer AJR, Agricola R et al. Osteoarthritis. Lancet. 2015; 386(9991): 376-87.
3. Romanowski W. Choroba zwyrodnieniowa stawów. In: Olesińska M (ed). Reumatologia. PZWL, Warszawa 2019: 279-90.
4. Kucharz EJ, Kovalenko V, Szántó S et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016; 32: 997-1004.
5. Kucharz EJ. Leczenie farmakologiczne choroby zwyrodnieniowej. Twój Magazyn Med. 2003; 8(14-131): 49-56.
6. Kucharz EJ. Zachowawcze leczenie choroby zwyrodnieniowej stawów. Terapia. 2007; 15(12): 21-6.
7. Kucharz EJ. Hit two birds with one stone: why crystalline glucosamine sulphate used for osteoarthritis medication is beneficial for patients with risk of cardiovascular disorders. Reumatologia. 2019; 57: 306.
8. Kucharz EJ. Zastosowanie mieszaniny niezmydlających się składników olejów z awokado i soi (piaskledyny) w leczeniu choroby zwyrodnieniowej stawów. Ortop Traumatol Rehabil. 2003; 5: 248-51.
9. Henrotin YE, Labasse AH, Jaspar JM et al. Effects of three avocado/soyabean unsaponifiable mixture on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheum. 1998; 17: 31-9.
10. Mauviel A, Daireaux M, Hartman DJ et al. Effets insaponifiables d’avocado/soja sur la production de collagene par des cultures de synoviocytes, chondrocytes articulaires et fibroblastes dermiques. Rev Rhum. 1989; 56: 207-13.
11. Boumediene K, Felisaz N, Bogdanowicz P et al. Avocado/soyabean unsaponifiables enhance the expression of transforming growth factor β1 and β2 in cultured articular chondrocytes. Arthritis Rheum. 1999; 42: 148-56.
12. Blotman F, Maheu E, Wulwik A et al. Efficacy and safety of avocado/soyabean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997; 64: 825-34.
13. Appelboom T, Schuermans J, Verbruggen G et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol. 2001; 30: 242-7.
14. Lequesne M, Maheu E, Cadet C et al. Effect of avocado/soya unsaponifiables on joint space loss in hip osteoarthritis over 2 years. A placebo controlled trial. Arthritis Rheum. 1996; 39: S227.
15. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016; 54: 217-26.
16. Honvo G, Reginster JY, Rabenda V et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a systematic review and meta- -analysis. Drugs Aging. 2019; 36(suppl 1): 65-99.